Using prognostic models in CLL to personalize approach to clinical care: Are we there yet? |
| |
| Authors: | Alain Mina Jose Sandoval Sus Elsa Sleiman Javier Pinilla-Ibarz Farrukh T Awan Mohamed A Kharfan-Dabaja |
| |
| Institution: | 1. Dept. of Internal Medicine, Kansas University Medical Ctr, Kansas City, KS, USA;2. Dept. of Malignant Hematology, Moffitt Cancer Ctr, Tampa, FL, USA;3. Faculty of Medicine, American Univ. of Beirut, Beirut, Lebanon;4. Department of Oncologic Sciences, Moffitt Cancer Ctr, Univ. of South Florida Morsani College of Medicine, Tampa, FL, USA;5. Div. of Hematology, Dept. of Internal Medicine, The Ohio State Univ. Comprehensive Cancer Ctr, Columbus, OH, USA;6. Dept. of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Ctr, Tampa, FL, USA |
| |
| Abstract: | Four decades ago, two staging systems were developed to help stratify CLL into different prognostic categories. These systems, the Rai and the Binet staging, depended entirely on abnormal exam findings and evidence of anemia and thrombocytopenia. Better understanding of biologic, genetic, and molecular characteristics of CLL have contributed to better appreciating its clinical heterogeneity. New prognostic models, the GCLLSG prognostic index and the CLL-IPI, emerged. They incorporate biologic and genetic information related to CLL and are capable of predicting survival outcomes and cases anticipated to need therapy earlier in the disease course. Accordingly, these newer models are helping develop better informed surveillance strategies and ultimately tailor treatment intensity according to presence (or lack thereof) of certain prognostic markers. This represents a step towards personalizing care of CLL patients. We anticipate that as more prognostic factors continue to be identified, the GCLLSG prognostic index and CLL-IPI models will undergo further revisions. |
| |
| Keywords: | Chronic lymphocytic leukemia Prognostic staging systems Survival |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
